Alnylam Pharmaceuticals EBIT

Alnylam Pharmaceuticals's ebit stands at $550M as of March 2026. That compares with $-160M in the prior-year period — up 446.6% year over year. That is below the Healthcare sector average of $23B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Alnylam Pharmaceuticals reported $550M in EBIT versus $-160M a year earlier — a 446.6% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Alnylam Pharmaceuticals sits lower the Healthcare benchmark ($23B) with a EBIT of $550M. That is roughly 97.6% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-160M in the prior-year period — up 446.6% year over year. Sustained growth in EBIT can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Alnylam Pharmaceuticals's EBIT evolved across reporting periods, while the comparison chart places ALNY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.